Detection of minimal residual disease in B-lymphoproliferative disorders: A three step SSCP-PCR method

M. Miglino, R. Grasso, D. Pietrasanta, G. L. Palmisano, G. Berisso, M. Clavio, I. Pierri, G. Santini, L. Canepa, M. Gobbi

Research output: Contribution to journalArticle

Abstract

The most recent therapeutic approaches can improve the outcome of B-cell neoplasia. By PCR analysis we amplify tumor specific DNA sequences of clonal IgH rearrangement from a limited number of malignant cells against a background of normal B cells. Recently described PCR based techniques for tracking minimal residual disease (MRD) in B lymphoproliferative disorders have given promising but discordant results, with significant variations in the sensitivity and specificity of the procedures. We have developed a three step single strand conformational polymorphism polymerase chain reaction (SSCP-PCR) strategy which is able to detect clonal malignant cells in B lymphoproliferative disorders at a frequency as low as 1 in 106 cells. Since this method is simple, rapid, reliable and as specific as ASO-PCR, it could be especially useful in monitoring patients affected by B lymphoproliferative disorders in complete haematological and immunophenotypic remission.

Original languageEnglish
Pages (from-to)95-101
Number of pages7
JournalJournal of Experimental and Clinical Cancer Research
Volume20
Issue number1
Publication statusPublished - 2001

Keywords

  • B lymphoid malignancies
  • IgH gene rearrangement
  • MRD
  • Nested PCR

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Detection of minimal residual disease in B-lymphoproliferative disorders: A three step SSCP-PCR method'. Together they form a unique fingerprint.

  • Cite this

    Miglino, M., Grasso, R., Pietrasanta, D., Palmisano, G. L., Berisso, G., Clavio, M., Pierri, I., Santini, G., Canepa, L., & Gobbi, M. (2001). Detection of minimal residual disease in B-lymphoproliferative disorders: A three step SSCP-PCR method. Journal of Experimental and Clinical Cancer Research, 20(1), 95-101.